Radium-223 dichloride in prostate cancer: proof of principle for the use of targeted alpha treatment in clinical practice-Reference-Cited by-同舟云学术

Radium-223 dichloride in prostate cancer: proof of principle for the use of targeted alpha treatment in clinical practice

Published:2019-08-30 Issue:1 Volume:47 Page:192-217
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Dizdarevic Sabina^ORCID,McCready Ralph,Vinjamuri Sobhan

Publisher

Springer Science and Business Media LLC

Subject

Radiology Nuclear Medicine and imaging,General Medicine,Radiology Nuclear Medicine and imaging,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00259-019-04475-5.pdf

Reference53 articles.

1. Sofou S. Radionuclide carriers for targeting of cancer. Int J Nanomedicine. 2008;3:181–99.

2. Marcu L, Bezak E, Allen BJ. Global comparison of targeted alpha vs targeted beta therapy for cancer: in vitro, in vivo and clinical trials. Crit Rev Oncol Hematol. 2018;123:7–20.

3. Sartor O, Sharma D. Radium and other alpha emitters in prostate cancer. Transl Androl Urol. 2018;7:436–44.

4. Bayer. Xofigo Summary of Product Characteristics. 2018. Available from: https://www.medicines.org.uk/emc/product/5204/smpc . Accessed 13 Dec 2018.

5. Bayer. Xofigo Prescribing Information. 2018. Available from: http://labeling.bayerhealthcare.com/html/products/pi/Xofigo_PI.pdf . Accessed 13 Dec 2018.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials;Breast Cancer Research and Treatment;2023-12-20

2. Prognostic value of neutrophil‐to‐lymphocyte ratio in patients with metastatic castration‐resistant prostate cancer receiving prostate‐specific membrane antigen targeted radionuclide therapy;The Prostate;2023-07-09

3. References;An Insider's Perspective of Prostate Cancer;2023

4. Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials;2022-12-02

5. Tailoring radiotherapies and nanotechnology for targeted treatment of solid tumors;Coordination Chemistry Reviews;2022-12